FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
--

OMB APPROVAL											
OMB Number: 3235-028											
Estimated average burden											
hours per response:	0.5										

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Burns James William (Last) (First) (Middle) 88 SIDNEY STREET					3. D	2. Issuer Name and Ticker or Trading Symbol AGIOS PHARMACEUTICALS, INC. AGIO] 3. Date of Earliest Transaction (Month/Day/Year) 02/22/2022									ck all appli Directo Officer below)	onship of Reporting Person(s) to Issuer III applicable) Director 10% Owner Officer (give title below) Chief Legal Officer			
(Street) CAMBR (City)		tate)	02139 (Zip)			4. If Amendment, Date of Original Filed (Month/Day/Year)									ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Tabl	e I - No	n-Deriv	ative	Sec	uritie	es Ac	quired	, Dis	posed o	of, or B	enefi	cially	Owne	d 			
1. Title of Security (Instr. 3)				2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Code	Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)			5. Amou Securitie Benefici Owned I Reporte	es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) o	r Pri	ice	Transac	nsaction(s) tr. 3 and 4)			(111541. 4)
Common stock				02/22	2/2022				М		724	A		\$ <mark>0</mark>	15,008			D	
Common stock 02/22/2				/2022	2022		F		215	215 D \$		29.08	14,793			D			
		Т	able II -						,		osed of converti	,		•	Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date, Transa Code (6. Date E: Expiratio (Month/D	n Date	Amount of Securities Underlying Derivative Sec (Instr. 3 and 4)		of s ng e Secu and 4)	rity	. Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s llly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amo or Num of Shar	ber					
Restricted	(1)	02/22/2022			M			724	(2)		(2)	Common	72	4	\$0	0		D	

Explanation of Responses:

- 1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- 2. The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments.

/s/ William Cook, as Attorney in Fact for James Burns

02/23/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.